- | Country : -
- | organs : -
- | Specialty : -
Extract
To determine the benefit of enzalutamide plus ADT as compared to placebo plus ADT as assessed by radiographic progression-free survival (rPFS) based on central review
Inclusion criteria
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)